

Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

NOVADEL PHARMA INC  
Form 10QSB  
March 16, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2004

TRANSITION REPORT UNDER SECTION 13 or 15 (d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 000-23399

NOVADEL PHARMA INC.  
(Exact name of small business issuer as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

22-2407152  
(I.R.S. Employer  
Identification No.)

25 Minneakoning Road  
Flemington, New Jersey  
(Address of Principal Executive Offices)

08822  
(Zip Code)

(908) 782-3431  
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No \_\_\_

APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 32,877,642 shares of common stock outstanding as of March 9, 2004.

# Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

## ITEM 1. FINANCIAL STATEMENTS

### NOVADEL PHARMA INC.

#### CONDENSED BALANCE SHEETS

|  | January 31,<br>2004  | July 31,<br>2003  |
|--|----------------------|-------------------|
|  | -----<br>(Unaudited) | -----<br>(Note 1) |
| <b>ASSETS</b>  |                      |                   |
| <b>CURRENT ASSETS:</b>   |                      |                   |
| Cash   | \$ 12,840,000        | \$ 3,086,000      |
| Accounts receivable - trade  | 28,000               | 2,000             |
| Prepaid expenses and other current assets  | 338,000              | 168,000           |
|  | -----                | -----             |
| Total Current Assets   | 13,206,000           | 3,256,000         |
|  | -----                | -----             |
| FURNITURE, FIXTURES, AND EQUIPMENT, LESS<br>ACCUMULATED DEPRECIATION                     | 1,025,000            | 714,000           |
| OTHER ASSETS   | 355,000              | 357,000           |
|  | -----                | -----             |
|  | \$ 14,586,000        | \$ 4,327,000      |
|  | =====                | =====             |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>  |                      |                   |
| <b>CURRENT LIABILITIES:</b>  |                      |                   |
| Accounts payable-trade   | \$ 73,000            | \$ 139,000        |
| Accrued expenses and other current liabilities   | 552,000              | 318,000           |
| Current portion of deferred revenue  | 19,000               | --                |
| Current portion of capitalized lease obligation  | 26,000               | --                |
|  | -----                | -----             |
| Total Current Liabilities  | 670,000              | 457,000           |
|  | -----                | -----             |
| Non current portion of deferred revenue  | 353,000              | --                |
| Non current portion of capitalized lease obligation                                      | 49,000               | --                |
|  | -----                | -----             |
| Total Liabilities  | 1,072,000            | 457,000           |
|  | -----                | -----             |
| <b>COMMITMENTS AND CONTINGENCIES</b>   |                      |                   |
| <b>STOCKHOLDERS' EQUITY:</b>   |                      |                   |
| Preferred stock, \$.01 par value:  |                      |                   |
| Authorized 1,000,000 shares, none issued   |                      |                   |
| Common stock, \$.001 par value:  |                      |                   |
| Authorized - 50,000,000 shares   |                      |                   |
| Issued and outstanding 32,677,642 at January<br>31, 2004 and 17,972,760 at July 31, 2003 | 33,000               | 18,000            |
| Additional paid-in capital   | 32,250,000           | 19,480,000        |
| Accumulated deficit  | (18,769,000)         | (15,628,000)      |
|  | -----                | -----             |
| Total Stockholders' Equity   | 13,514,000           | 3,870,000         |
|  | -----                | -----             |
|  | \$ 14,586,000        | \$ 4,327,000      |

Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

=====

See accompanying notes to condensed financial statements.

2

NOVADEL PHARMA INC.

CONDENSED STATEMENTS OF OPERATIONS  
(Unaudited)

|  | Three Months Ended<br>January 31, |                | Six Months Ended<br>January 31, |                |
|--|-----------------------------------|----------------|---------------------------------|----------------|
|  | 2004                              | 2003           | 2004                            | 2003           |
| LICENSE FEE  | \$ 3,000                          | \$ --          | \$ 3,000                        | \$ --          |
| CONSULTING REVENUES  | 18,000                            | --             | 18,000                          | --             |
| TOTAL REVENUES   | 21,000                            | --             | 21,000                          | --             |
| RESEARCH AND DEVELOPMENT<br>EXPENSES                                 | 389,000                           | 348,000        | 678,000                         | 565,000        |
| CONSULTING, SELLING, GENERAL AND<br>ADMINISTRATIVE EXPENSES          | 1,265,000                         | 1,523,000      | 2,709,000                       | 3,035,000      |
| TOTAL EXPENSES   | 1,654,000                         | 1,871,000      | 3,387,000                       | 3,600,000      |
| LOSS FROM OPERATIONS   | (1,633,000)                       | (1,871,000)    | (3,366,000)                     | (3,600,000)    |
| INTEREST INCOME  | 5,000                             | 18,000         | 11,000                          | 33,000         |
| LOSS BEFORE INCOME TAXES   | (1,628,000)                       | (1,853,000)    | (3,355,000)                     | (3,567,000)    |
| DEFERRED INCOME TAX BENEFIT  | 214,000                           | 84,000         | 214,000                         | 84,000         |
| NET LOSS   | \$ (1,414,000)                    | \$ (1,769,000) | \$ (3,141,000)                  | \$ (3,483,000) |
| BASIC AND DILUTED LOSS PER SHARE                                     | \$ (.06)                          | \$ (.12)       | \$ (.15)                        | \$ (.24)       |
| SHARES USED IN COMPUTATION OF<br>BASIC AND DILUTED LOSS PER<br>SHARE | 23,247,336                        | 14,542,821     | 20,610,048                      | 14,526,172     |

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

See accompanying notes to condensed financial statements.

3

### NOVADEL PHARMA INC.

#### CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY SIX MONTHS ENDED JANUARY 31, 2004 (Unaudited)

|  | Common Stock |           | Additional<br>Paid-in<br>Capital | Acco<br>D |
|--|--------------|-----------|----------------------------------|-----------|
|  | Shares       | Amount    |                                  |           |
| BALANCE, August 1, 2003  | 17,972,760   | \$ 18,000 | \$ 19,480,000                    | \$ (1     |
| Stock issued in connection with private<br>placement, net of costs           | 13,333,333   | 14,000    | 12,771,000                       |           |
| Stock issued to 2003 private investors<br>in connection with reset provision | 1,371,549    | 1,000     | (1,000)                          |           |
| Net Loss   | --           | --        | --                               | (         |
| BALANCE, January 31, 2004  | 32,677,642   | \$ 33,000 | \$ 32,250,000                    | \$ (1     |

See accompanying notes to condensed financial statements.

4

### NOVADEL PHARMA INC.

#### CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

|   | Six Months Ended<br>January 31 |                |
|---|--------------------------------|----------------|
|   | 2004                           | 2003           |
| CASH FLOWS FROM OPERATING ACTIVITIES:         |                                |                |
| Net loss                                      | \$ (3,141,000)                 | \$ (3,483,000) |
| Adjustments to reconcile net loss to net cash |                                |                |

Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

|   |               |              |
|---|---------------|--------------|
| used in operating activities:   |               |              |
| Warrants issued for Services  | --            | 7,000        |
| Options Issued for Services   | --            | 1,198,000    |
| Shares issued for Warrants exercised  | --            | 10,000       |
| Depreciation & Amortization   | 105,000       | 74,000       |
| Changes in operating assets and liabilities:  |               |              |
| Accounts receivable   | (26,000)      | 1,000        |
| Prepaid expenses and other current assets   | (170,000)     | (65,000)     |
| Other Assets  | 2,000         | (4,000)      |
| Accounts payable - trade  | (66,000)      | 243,000      |
| Accrued expenses and other current liabilities  | 234,000       | 338,000      |
| Deferred revenue  | 372,000       | --           |
|   | -----         | -----        |
| Net cash used in operating activities   | (2,690,000)   | (1,681,000)  |
|   | -----         | -----        |
| CASH FLOWS FROM INVESTING ACTIVITIES -  |               |              |
| Purchase of property and equipment  | (329,000)     | (109,000)    |
|   | -----         | -----        |
| CASH FLOWS FROM FINANCING ACTIVITIES:   |               |              |
| Proceeds received from issuance of common stock through<br>a private placement offering | 12,785,000    | --           |
| Payments of capitalized lease obligation  | (12,000)      | --           |
|   | -----         | -----        |
| Net cash provided by financing activities   | 12,773,000    | --           |
|   | -----         | -----        |
| NET INCREASE (DECREASE) IN CASH   | 9,754,000     | (1,790,000)  |
| CASH, BEGINNING OF PERIOD   | 3,086,000     | 3,314,000    |
|   | -----         | -----        |
| CASH, END OF PERIOD   | \$ 12,840,000 | \$ 1,524,000 |
|   | =====         | =====        |
| SUPPLEMENTAL DISCLOSURE OF INVESTING AND<br>FINANCING ACTIVITIES:                       |               |              |
| Equipment acquired under capitalized lease obligation                                   | \$ 87,000     | \$ --        |
|   | =====         | =====        |

See accompanying notes to condensed financial statements.

NOVADEL PHARMA INC.  
NOTES TO CONDENSED FINANCIAL STATEMENTS

NOTE 1 - BASIS OF PRESENTATION:

The balance sheet at the end of the preceding fiscal year has been derived from the audited balance sheet contained in the previously filed Form 10-KSB of NovaDel Pharma Inc. (the Company) for the year ended July 31, 2003 and is presented for

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

comparative purposes. All other financial statements are unaudited. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the financial position, results of operations and cash flows for all periods presented, have been made in the interim financial statements. Results of operations for interim periods are not necessarily indicative of the operating results to be expected for a full year.

Management of the Company believes that during the second calendar quarter of 2005, it will be necessary for the Company to obtain additional financing and/or consummate a well funded strategic alliance with a business partner. There are a number of risks and uncertainties related to the Company's attempt to complete a financing or strategic partnering arrangement that are outside the control of the Company. The Company may not be able to successfully obtain additional financing on terms acceptable to the Company, or at all.

Certain footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted in accordance with the published rules and regulations of the Securities and Exchange Commission. The condensed financial statements in this report should be read in conjunction with the financial statements and notes thereto included in the Form 10-KSB for the year ended July 31, 2003.

### NOTE 2 - LOSS PER COMMON SHARE

Loss per common share is computed pursuant to SFAS No. 128, "Earnings Per Share." Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and convertible debt. As of January 31, 2004, 20,110,429 (17,322,358 if the amendment to the Company's Certificate of Incorporation is not approved) of options and warrants were excluded from the diluted loss per share computation, as their effect would be anti-dilutive. The Company has outstanding derivative securities (options and warrants) which exceed the Company's authorized and unissued stock under its Certificate of Incorporation. The Company has a Proposal pending for its Annual Meeting (presently scheduled for April 19, 2004) to amend its Certificate of Incorporation to increase its authorized common stock from 50,000,000 shares to 100,000,000 shares. The Company's stockholders may not approve that amendment. In that case, we may not have a sufficient number of shares available to honor the exercise of such derivative securities; any liability incurred by us in such an eventuality could have a material adverse effect upon the Company.

### NOTE 3 - CAPITALIZED LEASE OBLIGATION:

In October 2003, the Company entered into a capital lease for laboratory equipment. This lease requires 36 monthly payments of \$2,827 each.

### NOTE 4 - CONTRACTS:

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

In August 2003, Mr. Robert C. Galler agreed to change from an employee of the Company as Vice President - Corporate Development to a consultant and entered into a consulting agreement with the Company at a base compensation of \$180,000 per year. The consulting agreement terminates in February 2005.

6

### NOTE 5 - STOCK OPTIONS AND WARRANTS:

The Company follows the intrinsic value method of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" (APB 25) and related interpretations in accounting for its employee stock options because, in the opinion of management, as discussed below, Financial Accounting Standards Board Statement No. 123, "Accounting for Stock-Based Compensation" (FAS 123) requires use of option valuation models that were not developed for use in valuing employee stock options. FAS 123 permits a company to elect to follow the intrinsic value method of APB 25 rather than the alternative fair value accounting method provided under FAS 123, but requires pro forma net income (loss) and earnings (loss) per share disclosures as well as various other disclosures. The Company has adopted the disclosure provisions required under Financial Accounting standards Board Statement No. 148, "Accounting for Stock-Based Compensation-Transition and Disclosure" (FAS 148). Under APB 25, because the exercise price of the Company's stock options has equaled the market price of the underlying stock on the date of grant, no compensation expense was recognized.

Pro forma information regarding net loss and loss per share required by FAS 123 and FAS 148, has been determined as if the Company had accounted for its employee stock options under the fair value method of Statement 123.

The fair value of options granted during the three and six months periods ending January 31, 2004 were estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions, respectively: risk-free interest rates of 4.0%, dividend yield of 0.0%, volatility factors of the expected market price of the Company's common stock of 54% for the three months ending January 31, 2004 and 57% for the six months ending January 31, 2004, and a weighted-average expected life of the options of eight years for the three months ending January 31, 2004 and nine years for the six months ending January 31, 2004.

For purposes of pro forma disclosures, the estimated fair value of options is amortized to expense over the options' vesting periods. The Company's pro forma information follows:

3 MONTHS ENDED  
JANUARY 31,

Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

|   | 2004<br>-----           | 2003<br>-----           |
|---|-------------------------|-------------------------|
| Net Loss, as reported   | \$ (1,414,000)          | \$ (1,769,000)          |
| Stock-based employee compensation expense<br>under fair value method, net of related<br>tax effects | (46,000)                | --                      |
| Pro forma net loss  | \$ (1,460,000)<br>===== | \$ (1,769,000)<br>===== |
| Loss per share:   |                         |                         |
| Basic and diluted, as reported  | \$ (.06)<br>=====       | \$ (.12)<br>=====       |
| Basic and diluted, pro forma  | \$ (.06)<br>=====       | \$ (.12)<br>=====       |

|   | 6 MONTHS ENDED<br>JANUARY 31,<br>----- |                         |
|---|--|-------------------------|
|   | 2004<br>-----                          | 2003<br>-----           |
| Net Loss, as reported   | \$ (3,141,000)                         | \$ (3,483,000)          |
| Stock-based employee compensation expense<br>under fair value method, net of related<br>tax effects | (56,000)                               | --                      |
| Pro forma net loss  | \$ (3,197,000)<br>=====                | \$ (3,483,000)<br>===== |
| Loss per share:   |  |                         |
| Basic and diluted, as reported  | \$ (.15)<br>=====                      | \$ (.24)<br>=====       |
| Basic and diluted, pro forma  | \$ (.16)<br>=====                      | \$ (.24)<br>=====       |

7

In August 2003, the Company issued 75,000 options under the 1998 Option Plan to a new employee. These options vest equally over 3 years, beginning August 1, 2004, have an exercise price of \$2.23 per share and expire during July 2013.

In August 2003, the Company issued 6,000 options under the 1998 Option Plan to a new employee. These options vest equally over 3 years, beginning August 19, 2004, have an exercise price of \$1.99 per share and expire during August 2013.

In September 2003, the Company issued 100,000 Non-plan Options to a new director. These options vest equally over 3 years, beginning September 9, 2004, have an exercise price of \$1.85 per share and expire during September 2008.

In October 2003, the Company issued 60,000 options under the



## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

1998 Option Plan to a new employee. These options vest equally over 3 years, beginning October 24, 2004, have an exercise price of \$2.10 per share and expire during October 2013.

In November 2003, the Company issued 6,000 options under the 1998 Option Plan to a new employee. These options vest equally over 3 years, beginning November 25, 2004, have an exercise price of \$1.60 per share and expire during November 2013.

In December 2003, the Company issued 50,000 options under the 1998 Option Plan to a new employee. These options vest equally over 3 years, beginning December 22, 2004, have an exercise price of \$1.45 per share and expire during December 2013.

In December 2003, the Company issued 75,000 options under the 1998 Option Plan to a new employee. These options vest equally over 3 years, beginning December 29, 2004, have an exercise price of \$1.50 per share and expire during December 2013.

In January 2004, the Company issued 20,000 options under the 1998 Option Plan to a new employee. These options vest equally over 3 years, beginning January 12, 2005, have an exercise price of \$1.59 per share and expire during January 2014.

On November 18, 2003, the Company's publicly traded warrants expired.

NOTE 6 -

### RELATED PARTY TRANSACTIONS:

In April 2003, the Company entered into a license and development agreement with Manhattan Pharmaceuticals, Inc., for the worldwide, exclusive rights to the Company's proprietary lingual spray technology. One of the Company's significant stockholders is also a significant stockholder of Manhattan Pharmaceuticals, Inc.

During the six months ended January 31, 2004, the Company invoiced Manhattan Pharmaceuticals, Inc. approximately \$220,000 for the Company's reimbursable expenses of which payment of approximately \$148,000 was received prior to January 31, 2004. In November 2003, the Company received \$375,000 from Manhattan Pharmaceuticals, Inc., for license fees. The Company expects to recognize these license fees over the 20 year term of the license.

NOTE 7 -

### PRIVATE PLACEMENT:

During January 2004, the Company completed a private placement and received net proceeds of approximately \$12,785,000 from the placement of a total of 140 units of the Company's securities. Each unit consisted of ninety five thousand two hundred thirty eight (95,238) common shares, par value \$.001 and twenty eight thousand five hundred seventy one (28,571) warrants. Each warrant entitles the holder to purchase an additional share of the Company's common stock at an exercise price of \$1.40 within five (5) years. The sale price of each unit was \$100,000 (\$1.05 per share). A total of 13,333,333 shares and approximately 4,000,000 warrants were issued.

The securities were sold through Paramount Capital, Inc., a NASD broker-dealer ("Paramount"). For its services as

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

placement agent, the Company paid Paramount a 7% commission fee of the aggregate amount raised and also issued to Paramount (and its designees) unit purchase options to purchase 1,330,303 shares of common stock at an exercise price of \$1.40 per share and warrants to purchase an additional 399,091 shares of common stock at an

8

exercise price of \$1.40 per share. The Company also paid Paramount a non-accountable expense allowance of \$25,000 to reimburse Paramount for its out-of-pocket expenses. A significant stockholder of the Company is a controlling principal of Paramount.

In connection with the Company's April/May 2003 private placement, the Company had agreed, for a period of one year, that if the Company issued shares of common stock at a per share price less than \$1.50 (the price per share in such offering) that such investors would receive "reset price" shares without any additional consideration being paid to the Company (so that those investors would receive additional shares as if they purchased their shares at such lower per share purchase price). The per share sale price of the January 2004 offering triggered the reset rights of such investors and 1,371,549 shares were issued to these investors for no additional consideration.

### NOTE 8 - SUBSEQUENT EVENTS:

In February 2004, the Company issued 100,000 Non-plan options to a new director. These options vest equally over 3 years, beginning February 23, 2005, have an exercise price of \$1.65 per share and expire during February 2009.

In February 2004, 200,000 options were exercised for cash, yielding proceeds to the Company of \$200,000.

9

NOVADEL PHARMA INC.

### ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

Novadel Pharma Inc., a Delaware corporation (the "Company"), is engaged in development of novel application drug delivery systems for presently marketed prescription and over-the-counter ("OTC") drugs and has been a consultant to the pharmaceutical industry. Since 1992, the Company has used its consulting

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

revenues to fund its own product development activities.

Since its inception, substantially all of the Company's revenues have been derived from its consulting activities. The Company has had a history of recurring losses from operations, giving rise to an accumulated deficit at January 31, 2004 of \$18,769,000.

For the reasons stated above, the Company anticipates that it will incur substantial operating expenses in connection with the testing and approval of its proposed delivery systems, and expects these expenses will result in continuing and significant operating losses until such time, if ever, that the Company is able to achieve adequate sales levels.

### RESULTS OF OPERATIONS

THE SIX MONTHS ENDED JANUARY 2004 [THE "2004 PERIOD"] AND JANUARY 2003 [THE "2003 PERIOD"]

Operating revenues for the 2004 Period increased approximately \$21,000 from \$0 for the 2003 Period.

Total expenses for the 2004 Period decreased approximately \$213,000 or 6% to \$3,387,000 from \$3,600,000 for the 2003 Period. This decrease includes approximately: \$978,000 in consultants fees primarily due to a non-cash charge for options issued to a consultant during the 2003 Period; \$125,000 in cost of clinical studies primarily due to fewer studies during the 2004 Period and \$17,000 in trade show and conference expenses. Expense increases for the 2004 Period, as compared to the 2003 Period, include approximately: \$473,000 in payroll expense primarily due to the hiring of additional employees; \$145,000 in rent expense due to the leasing and occupying of additional space during the first fiscal quarter; \$39,000 in insurance expenses due to additional employees and generally increased premiums; \$45,000 in outside services due to increased activity; \$42,000 in employee recruiting; \$15,000 in depreciation and amortization expense due to the earlier purchases of internal laboratory equipment; \$26,000 in public company expense due to an increased number of directors; \$20,000 in inside laboratory expenses; \$20,000 in travel expenses; \$17,000 in telephone expense; \$16,000 in office expenses due to additional employees and \$16,000 in supplies expense necessary for sample products.

Interest income decreased approximately \$22,000 or 67% to \$11,000 for the 2004 Period from \$33,000 for the 2003 Period due to a decreased average cash balance.

Deferred income tax benefit for the 2004 period was approximately \$214,000 compared to approximately \$84,000 for the 2003 period. These benefits resulted from the sale of the Company's New Jersey net operating losses.

The resulting net loss for the 2004 Period was \$3,141,000 (or \$.15 per share) compared to a net loss of \$3,483,000 (or \$.24 per share) for the 2003 Period.

THE THREE MONTHS ENDED JANUARY 2004 [THE "2004 PERIOD"] AND JANUARY 2003 [THE "2003 PERIOD"]

Operating revenues for the 2004 Period increased approximately \$21,000 from \$0

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

from the 2003 Period.

Total expenses for the 2004 Period decreased approximately \$217,000 or 12% to \$1,654,000 from \$1,871,000 for the 2003 Period. This decrease includes approximately: \$480,000 in consultants fees primarily due to a non-cash charge for options issued to a consultant during the 2003 Period; \$49,000 in employee recruiting and \$20,000 in legal and professional fees. Expense increases for the 2004 period, as compared to the 2003 period, include approximately: \$105,000 in payroll expense primarily due to the hiring of additional employees; \$100,000 in rent expense due to the leasing and occupying of additional space during the first fiscal quarter; \$30,000 in cost of clinical studies; \$24,000 in insurance expenses due to additional employees and generally increased premiums; \$21,000 in inside laboratory expenses; \$18,000 in depreciation and amortization expense due to the earlier purchases of internal laboratory equipment; \$14,000 in public company expense due to an increased number of directors and \$14,000 in outside services due to increased activity.

Interest income decreased approximately \$13,000 or 72% to \$5,000 for the 2004 Period from \$18,000 for the 2003 Period due to a decreased average cash balance.

Deferred income tax benefit for the 2004 period was approximately \$214,000 compared to approximately \$84,000 for the 2003 period. These benefits resulted from the sale of the Company's New Jersey net operating losses.

The resulting net loss for the 2004 Period was \$1,414,000 (or \$.06 per share) compared to a net loss of \$1,769,000 (or \$.12 per share).

### LIQUIDITY AND CAPITAL RESOURCES

Net cash used in operating activities approximated \$2,690,000 for the 2004 Period compared to net cash used in operating activities of approximately \$1,681,000 for the 2003 Period. Net cash used in operating activities for both the 2004 and 2003 periods was primarily attributable to the net loss of \$3,141,000 and \$3,483,000, respectively. For the 2004 period, \$329,000 was used for investing activities compared to \$109,000 for the 2003 Period. For the 2004 period, \$12,773,000 was received from financing activities as a result of the completion of a private offering of Units (consisting of common stock and warrants). Total cash flow for the 2004 period increased approximately \$9,754,000 as compared to a \$1,790,000 decrease for the 2003 period.

During January 2004, the Company completed a private placement and received net proceeds of approximately \$12,785,000. (See Part I, Note 7)

The Company believes that it currently has sufficient cash to satisfy its cash requirements into the second calendar quarter of 2005. However, beyond this point there is substantial doubt about the Company's ability to continue operations without obtaining additional financing and/or consummating a well-funded strategic alliance with a business partner. There are a number of risks and uncertainties related to the Company's attempt to complete a financing or strategic partnering arrangement that are outside the control of the Company. We may not be able to successfully obtain additional financing on terms acceptable to the Company, or at all. (See Part 1, Note 1)

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

The Company has no off balance sheet arrangements within the meaning of SEC rules.

### INFLATION

The Company does not believe that inflation has had a material effect on its results of operations during the past three fiscal years. There can be no assurance that the Company's business will not be affected by inflation in the future.

### ITEM 3. CONTROLS AND PROCEDURES

As of January 31, 2004, our Chief Executive Officer and Chief Financial Officer performed an evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in SEC Rule 13a-15(e)), which have been designed to ensure that material information related to the Company is made known to them and timely disclosed. The Company's management, including the CEO and CFO, does not expect that the Company's disclosure controls or internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Notwithstanding the foregoing, however, based upon their evaluations, our CEO and CFO concluded that the Company's disclosure controls are effective to provide a reasonable level of assurance that material information relating to the Company is accumulated and communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

During the three months ended January 31, 2004, there have been no significant changes in our internal controls over financial reporting or in other factors, which have significantly affected, or are reasonable likely to significantly affect, our internal controls over financial reporting subsequent to such evaluation.

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

N/A

### ITEM 2. CHANGES IN SECURITIES AND SMALL BUSINESS ISSUER PURCHASES OF SECURITIES

In January 2004, the Company sold units (consisting of common stock and warrants) to accredited investors (at \$100,000 per Unit). Investors were issued three warrants for each ten shares purchased. A total of 13,333,333 shares and 3,999,957 warrants were issued. The warrants are exercisable for five years, at an exercise price of \$1.40 per share. The securities were sold through Paramount Capital, Inc., a NASD broker - dealer and a related party. The gross proceeds of the private offering were approximately \$14.0 million. For its services as placement agent, the Company paid Paramount a 7% commission fee of the aggregate amount raised (approximately \$980,000) and also issued to Paramount options to purchase 14 units at an exercise price of \$110,000 per unit for five years. The shares were sold pursuant to Regulation D and/or Section 4 (2) of the Act. (See Part I, Note 7) The per share price (\$1.05) of this sale triggered the reset

## Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

rights of certain prior investors and 1,371,549 shares were issued to these investors.

### ITEM 3. DEFAULTS UPON SENIOR SECURITIES

N/A

### ITEM 4. SUBMISSIONS OF MATTERS TO A VOTE OF SECURITY HOLDERS

N/A

12

### ITEM 5. OTHER INFORMATION

N/A

### ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

#### a) List of Exhibits

Exhibit 31.1 Rule 13a-14(a) Certification of Chief Executive Officer

Exhibit 31.2 Rule 13a-14(a) Certification of Chief Financial Officer

Exhibit 32.1 Certification under 18 U.S.C. 1350

Exhibit 32.2 Certification under 18 U.S.C. 1350

#### b) Reports on Form 8-K

1. Current report on Form 8-K filed December 3, 2003 disclosing the Company's Change in Certifying Accountant.
2. Current report on Form 8-K filed December 30, 2003 disclosing private placement of securities.
3. Current report on Form 8-K/A filed January 6, 2004 relating to Change in Certifying Accountant.
4. Current report on Form 8-K filed January 12, 2004 disclosing closing of private placement of securities.

13

## SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused

Edgar Filing: NOVADEL PHARMA INC - Form 10QSB

this report to be signed on its behalf by the undersigned thereunto duly authorized.

NOVADEL PHARMA INC

Dated: March 16, 2004

By: /s/ Gary A. Shangold, M.D.

-----  
Gary A. Shangold, M.D.  
President & Chief Executive Officer

Dated: March 16, 2004

By: /s/ Donald J. Deitman

-----  
Donald J. Deitman  
Chief Financial Officer